Trump takes credit for Pfizer vaccine development, says Americans wouldn’t have one yet without his leadership  Fox NewsView Full Coverage on Google News
Pfizer announced it applied for emergency authorization use for its vaccine candidate on Friday.Pfizer announced it applied for emergency authorization use for its vaccine candidate on Friday.

Health Secretary Matt Hancock reveals the government has now taken the "first step" for authorising a vaccine in the UK.Health Secretary Matt Hancock reveals the government has now taken the "first step" for authorising a vaccine in the UK.

COVID-19 vaccine: Pfizer coronavirus jab to be rolled out next month if approved by UK regulator, govt announces | Politics News | Sky News

Pfizer and BioNTech have submitted their covid-19 vaccine candidate to the US Food and Drug Administration (FDA) for emergency use authorisation, after concluding a phase III trial. The mRNA vaccine candidate, BNT162b2, was found to be 95% effective 28 days after the first dose. The phase III trial evaluated 170 confirmed cases of covid-19, 162 of which were observed in the placebo group. There were 10 severe cases, nine of which were in the placebo group. In its announcement, Pfizer said the vaccine could be available to high risk populations in the US by the end of December 2020. Globally, it plans to produce 50m doses in 2020 and up to 1.3bn doses by the end of 2021. The companies have started submission processes in Europe, as well as Australia, Canada, and Japan. The phase III trial began …

Covid-19: Pfizer and BioNTech submit vaccine for US authorisation | The BMJ

Academics hail good news for immunisation programmes after Oxford study shows those who recover are protected for at least half a yearAcademics hail good news for immunisation programmes after Oxford study shows those who recover are protected for at least half a year

Covid-19 patients ‘highly unlikely’ to contract illness again for at least six months say scientists

A government map showing the number of COVID-19 infections per capita on a county level for last week shows just how widespread COVID-19 has become across the United States.A government map showing the number of COVID-19 infections per capita on a county level for last week shows just how widespread COVID-19 has become across the United States.

COVID-19 US: Red wave map shows how widespread infection is | Daily Mail Online

He also explained whether those who actively have it could be vaccinatedHe also explained whether those who actively have it could be vaccinated

GMB's Dr Amir Khan on whether you can have vaccine if you've already had Covid-19 - Hull Live

403 Missing Auth Token

He also explained whether those who actively have it could be vaccinatedHe also explained whether those who actively have it could be vaccinated

TV GP Dr Amir Khan on whether you can have vaccine if you've already had Covid-19 - Wales Online

If we get mass rollout and uptake of vaccines, we can be cautiously optimisticIf we get mass rollout and uptake of vaccines, we can be cautiously optimistic

Will Covid-19 vaccines pave path back to normality?

All we really want for Christmas is a COVID vaccine.

EDITORIAL: A very merry shot in the arm | Toronto Sun

EDITORIAL: A very merry shot in the arm | Toronto Sun

On this, the week marking the anniversary of the first appearance in Hubei of SARS-CoV-2 in 2019, the biggest news is that there is good news at all. In an annus horibilis, we celebrate the breaks we get. On this, the week marking the anniversary of the first appearance in Hubei of SARS-CoV-2 in 2019, the biggest news is that there is good news at all. In an annus horibilis, we celebrate the breaks we get.

Chasing waterfalls | Philstar.com

THE Covid-19 vaccine developed by pharmaceutical giant Pfizer with BioNTech is already being looked at by regulators for a potential roll-out in December.THE Covid-19 vaccine developed by pharmaceutical giant Pfizer with BioNTech is already being looked at by regulators for a potential roll-out in December.

Covid vaccine ALREADY been looked at by UK regulator - decision on Pfizer jab in just days | Politics | News | Express.co.uk

The Government is hoping to start vaccinating against COVID-19 next month, with the bulk of the vaccination roll out in the New Year, Health Secretary Matt Hancock has announced this evening (Friday). The Pfizer BioNTech vaccine is now going through a rigorous analysis as a result of the Government formally asking the independent regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), to assess the vaccine with a view to authorising its use as soon as possible. Tonight's news is a massive breakthrough in the battle against COVID-19, with the Pfizer vaccine said to be 95% effective with no serious safety concerns. Other vaccines are also being created. Health Secretary Matt Hancock has said he is instructing the NHS to be ready to distribute the vaccine to population 'as fast as it can be produced', from as early as December. The vaccine will be available across the UK through the NHS, for free, and will be distributed based on need. Priority will be given to those at greatest risk. It's been confirmed that the vaccine will be delivered through vaccination centres, through vaccination hubs at hospitals and then, in the New Year, a community vaccination roll out through GPs and pharmacists. Furthermore, it has been announced tonight that free flu jabs will be made available for all over 50s from December.

COVID-19 VACCINE SET TO BE DISTRIBUTED FROM DECEMBER ANNOUNCES GOVERNMENT - Island Echo - 24hr news, 7 days a week across the Isle of Wight

Pfizer’s application with the FDA sets in motion a process that could bring limited shots as early as next month.Pfizer’s application with the FDA sets in motion a process that could bring limited shots as early as next month.

search

Health Secretary Matt Hancock gave an update in a Downing Street press conference Health Secretary Matt Hancock gave an update in a Downing Street press conference

Roll-out of Pfizer Covid-19 vaccine "could start next month" - if approved by safety regulator - Plymouth Live

Matt Hancock said the NHS was preparing to roll out a Covid-19 vaccine if one is approved for use.Matt Hancock said the NHS was preparing to roll out a Covid-19 vaccine if one is approved for use.

sign-in

Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.

Good News on Oxford’s COVID-19 Vaccine

The first COVID-19 vaccines to be given in the U.S. are expected to get a green light from regulators under a process known as emergency use authorizationThe first COVID-19 vaccines to be given in the U.S. are expected to get a green light from regulators under a process known as emergency use authorization

What does emergency use for a COVID-19 vaccine mean? Vaccine Food And Drug Administration Covid Process People | The Independent

A coronavirus vaccination program in the UK could begin next month if a jab is approved by the medicines regulator, the Health Secretary said on Friday. At a virtual Downing Street press conference, Matt Hancock revealed he had asked the Medicines and Healthcare products Regulatory Agency to assess the Pfizer/BioNTech vaccine, which trials suggest is 95 per cent effective. “If the regulator approves a vaccine we will be ready to start...

UK coronavirus LIVE: Matt Hancock says vaccination could begin next month as R rate falls closer to 1

The Oxford team behind a SARS-CoV-2 vaccine say they hope to have phase 3 trial results before Christmas.The Oxford team behind a SARS-CoV-2 vaccine say they hope to have phase 3 trial results before Christmas.

'Encouraging' Results for Older People From Oxford COVID-19 Vaccine

The Health Secretary is expected to speak about the coronavirus vaccine as England enters its third week of lockdownThe Health Secretary is expected to speak about the coronavirus vaccine as England enters its third week of lockdown

What time is the Government Covid announcement today? When to watch Matt Hancock's briefing and what to expect

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Health secretary Matt Hancock has said that he has formally asked the regulator to assess the Pfizer/BioNTech coronavirus vaccine for use in the UK.Health secretary Matt Hancock has said that he has formally asked the regulator to assess the Pfizer/BioNTech coronavirus vaccine for use in the UK.

Matt Hancock starts Covid vaccine approval process for 'New Year roll-out' | Eastern Daily Press

Emergency Use Authorization could pave the way for a rapid rollout of their coronavirus vaccine.Emergency Use Authorization could pave the way for a rapid rollout of their coronavirus vaccine.

Why Pfizer and BioNTech Stocks Rose Today | The Motley Fool

Vaccine candidate from Oxford University and AstraZeneca has shown promising results in older adults - Anadolu AgencyVaccine candidate from Oxford University and AstraZeneca has shown promising results in older adults - Anadolu Agency

Oxford vaccine produces promising response in elderly

Health Secretary Matt Hancock hailed the latest development in the hunt for a vaccine as "another important step forward in tackling this pandemic".Health Secretary Matt Hancock hailed the latest development in the hunt for a vaccine as "another important step forward in tackling this pandemic".

Covid-19 vaccine: When will it be ready and how can I get it? | ITV News

Pfizer Inc. undefined and BioNTech undefined on Friday submitted an application for an emergency use authorization for their trial COVID-19 vaccine...Pfizer Inc. undefined and BioNTech undefined on Friday submitted an application for an emergency use authorization for their trial COVID-19 vaccine...

Pfizer, BioNTech make it official: COVID-19 vaccine EUA submitted - MarketWatch

Health Secretary Matt Hancock is hosting Friday night's Downing Street press briefing in a week where the Pfizer, Moderna and Oxford University Covid-19 vaccines have all made promising breakthroughsHealth Secretary Matt Hancock is hosting Friday night's Downing Street press briefing in a week where the Pfizer, Moderna and Oxford University Covid-19 vaccines have all made promising breakthroughs

Brits could start getting Pfizer Covid vaccine as soon as next month, No.10 confirms - Daily Star

Catch up on the most important updates from this week.Catch up on the most important updates from this week.

Pfizer Seeks Vaccine Approval, the CDC Urges Restraint, and More Coronavirus News | WIRED

Health Secretary Matt Hancock is leading a Downing Street briefingHealth Secretary Matt Hancock is leading a Downing Street briefing

Matt Hancock explains how the coronavirus vaccine will be rolled out - Manchester Evening News

US News: WASHINGTON: US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towar.US News: WASHINGTON: US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towar.

Covid-19: Pfizer/BioNTech seek first vaccine approval in US - Times of India

Trump accused U.S. drugmaker Pfizer of waiting to announce the success of their Phase 3 vaccine trial until the day after the presidential election in order to avoid helping him.Trump accused U.S. drugmaker Pfizer of waiting to announce the success of their Phase 3 vaccine trial until the day after the presidential election in order to avoid helping him.

Trump turns on Pfizer over vaccine timing

AstraZeneca and Oxford have published the full coronavirus vaccine study detailing the strong immune response seen in older adults injected with their experimental drug in The Lancet. The COVID-19 vaccine is safe for the elderly and induces the desired immune response against the new virus.AstraZeneca and Oxford have published the full coronavirus vaccine study detailing the strong immune response seen in older adults injected with their experimental drug in The Lancet. The COVID-19 …

A third coronavirus vaccine might deliver results by Christmas – BGR

Employers can and should play a central role in getting Americans vaccinated.Employers can and should play a central role in getting Americans vaccinated.

How Employers Should Prepare For The Covid-19 Vaccine

Bloomberg - Are you a robot?

Pfizer and Moderna are seeking FDA approval for their vaccine candidates, though some questions remain.Pfizer and Moderna are seeking FDA approval for their vaccine candidates, though some questions remain.

Why the Pfizer and Moderna coronavirus vaccines seem to work better than expected

LONDON, Nov 20 ― A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said yesterday as it released its phase 2 trial results. The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side...LONDON, Nov 20 ― A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said yesterday as it released its phase 2 trial results. The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side...

Oxford Covid-19 vaccine safe for older adults, results show | Life | Malay Mail

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

GPs will not be required to deliver the majority of Covid-19 vaccinations that are administered this year, the health secretary has confirmed. In today’s Downing Street press briefing Matt Hancock said mass vaccination centres would deliver the bulk of the programme next month – and GPs would take a more prominent role in 2021. The

GPs will not deliver bulk of Covid-19 vaccines given this year, says Hancock - Pulse Today

Pfizer Reveals Their Coronavirus Vaccine Is 95% Effective After Completing Third Study Trial A new report from Pfizer has come out of their coronavirus vaccine trials about the success rate of the vaccine they have been developing to help eradicate the pandemic.…Read more here...

Pfizer Reveals Their Coronavirus Vaccine Is 95% Effective After Completing Third Study Trial | Coronavirus, health : Just Jared

AstraZeneca and the University of Oxford have confirmed that the COVID vaccine they are jointly developing has shown strong immune responses in adults in their 60s and 70s, with fuller results likely released before Christmas.AstraZeneca and the University of Oxford have confirmed that the COVID vaccine they are jointly developing has shown strong immune responses in adults in their 60s and 70s, with fuller results likely released before Christmas.

UK AstraZeneca Covid vaccine trial shows strong immune response in elderly — RT UK News

Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study's chief investigator said on Thursday. The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers.Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study's chief investigator said on Thursday. The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers.

Oxford COVID-19 trial will look at interim Phase III data after 53 infections - investigator

By Hari Kumar The race for a vaccine against Covid-19 is entering the home stretch and reports indicate one or more companies will soon get the go-ahead to begin mass production. Governments across the world have promised their citizens speedy access but the task facing authorities in transporting, storing and administering the doses is enormous. […]

Now the hard part: Why getting Covid vaccines to billions worldwide may take longer than hoped | Hong Kong Free Press HKFP